Following initial detections in neighboring South American countries, the H3N2 influenza A K subclade has now reached Argentina, with confirmed cases in Buenos Aires, Santa Cruz, and Neuquén, including hospitalizations for pneumonia. Authorities are advancing the 2026 flu vaccination campaign for at-risk groups, while current vaccines offer partial protection against severe illness, bolstered by antivirals like oseltamivir.
Building on earlier confirmations of the H3N2 K subclade in Chile, Peru, Colombia, and other regional nations, Argentina has now reported its first cases, verified through genetic sequencing at the Instituto Malbrán.
The infections include a 5-year-old child in Buenos Aires, two teenagers in Santa Cruz, and in Neuquén, a minor and an adult both hospitalized with pneumonia but who have recovered. This variant's higher transmissibility has prompted swift action.
Though not more lethal than typical H3N2, it spreads more efficiently, with symptoms such as high fever (>39°C), severe fatigue, persistent cough, headache, and in children, gastrointestinal distress.
Health officials are considering starting the 2026 vaccination drive earlier than the usual March-April for vulnerable groups: children under 2, adults over 65, pregnant women, healthcare workers, and those with comorbidities, pending production logistics. Neuquén Health Minister Martín Regueiro emphasized vigilance without alarm.
The existing vaccine provides protection against severe outcomes, and oseltamivir is advised for high-risk patients. Seek immediate care for breathing issues or chest pain.
